RecQL4 Inhibitors

Chemical inhibitors of RecQL4 comprise a diverse group of compounds that predominantly exert their effects through indirect mechanisms, primarily by modulating DNA replication, repair, and the genomic stability processes where RecQL4 is involved. The first category of these inhibitors includes agents like Camptothecin and Etoposide, which target topoisomerases I and II, respectively. These enzymes are crucial for DNA replication and repair, processes that are intricately connected to RecQL4's function. By inhibiting these topoisomerases, these compounds can disrupt the DNA replication and repair mechanisms, potentially impacting RecQL4's role in these processes.

The second category includes PARP inhibitors like Olaparib and Rucaparib, along with ATR kinase inhibitors. These compounds target key components of the DNA damage response, a pathway where RecQL4 plays a significant role. By modulating the response to DNA damage, these inhibitors can indirectly influence RecQL4's activity in DNA repair. Another significant category consists of DNA damaging agents such as Cisplatin, Mitomycin C, and Bleomycin. These compounds induce DNA damage and thereby necessitate the activation of DNA repair mechanisms, in which RecQL4 is involved. By increasing the burden of DNA damage, these agents can influence the functional dynamics of RecQL4. Other inhibitors like Hydroxyurea, Aphidicolin, and Gemcitabine disrupt DNA synthesis and replication, processes that are essential for cell cycle progression and genomic stability. By interfering with these processes, these compounds can indirectly impact RecQL4's activity in maintaining genomic integrity.